tetano
Editor, Senior Moderator
Nat Med
. 2022 Jan 19.
doi: 10.1038/s41591-021-01678-y. Online ahead of print.
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
Laura A VanBlargan[SUP] 1 [/SUP], John M Errico[SUP] 2 [/SUP], Peter J Halfmann[SUP] 3 [/SUP], Seth J Zost[SUP] 4 5 [/SUP], James E Crowe Jr[SUP] 4 5 6 [/SUP], Lisa A Purcell[SUP] 7 [/SUP], Yoshihiro Kawaoka[SUP] 3 8 9 [/SUP], Davide Corti[SUP] 10 [/SUP], Daved H Fremont[SUP] 2 11 12 [/SUP], Michael S Diamond[SUP] 13 14 15 16 17 [/SUP]
Affiliations
Abstract
The emergence of the highly transmissible B.1.1.529 Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody countermeasure efficacy because of the number of mutations in the spike protein. In this study, we tested a panel of anti-receptor-binding domain monoclonal antibodies (mAbs) corresponding to those in clinical use by Vir Biotechnology (S309, the parent mAb of VIR-7831 (sotrovimab)), AstraZeneca (COV2-2196 and COV2-2130, the parent mAbs of AZD8895 and AZD1061), Regeneron (REGN10933 and REGN10987), Eli Lilly (LY-CoV555 and LY-CoV016) and Celltrion (CT-P59) for their ability to neutralize an infectious B.1.1.529 Omicron isolate. Several mAbs (LY-CoV555, LY-CoV016, REGN10933, REGN10987 and CT-P59) completely lost neutralizing activity against B.1.1.529 virus in both Vero-TMPRSS2 and Vero-hACE2-TMPRSS2 cells, whereas others were reduced (COV2-2196 and COV2-2130 combination, ~12-fold decrease) or minimally affected (S309). Our results suggest that several, but not all, of the antibodies in clinical use might lose efficacy against the B.1.1.529 Omicron variant.
. 2022 Jan 19.
doi: 10.1038/s41591-021-01678-y. Online ahead of print.
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
Laura A VanBlargan[SUP] 1 [/SUP], John M Errico[SUP] 2 [/SUP], Peter J Halfmann[SUP] 3 [/SUP], Seth J Zost[SUP] 4 5 [/SUP], James E Crowe Jr[SUP] 4 5 6 [/SUP], Lisa A Purcell[SUP] 7 [/SUP], Yoshihiro Kawaoka[SUP] 3 8 9 [/SUP], Davide Corti[SUP] 10 [/SUP], Daved H Fremont[SUP] 2 11 12 [/SUP], Michael S Diamond[SUP] 13 14 15 16 17 [/SUP]
Affiliations
- PMID: 35046573
- DOI: 10.1038/s41591-021-01678-y
Abstract
The emergence of the highly transmissible B.1.1.529 Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody countermeasure efficacy because of the number of mutations in the spike protein. In this study, we tested a panel of anti-receptor-binding domain monoclonal antibodies (mAbs) corresponding to those in clinical use by Vir Biotechnology (S309, the parent mAb of VIR-7831 (sotrovimab)), AstraZeneca (COV2-2196 and COV2-2130, the parent mAbs of AZD8895 and AZD1061), Regeneron (REGN10933 and REGN10987), Eli Lilly (LY-CoV555 and LY-CoV016) and Celltrion (CT-P59) for their ability to neutralize an infectious B.1.1.529 Omicron isolate. Several mAbs (LY-CoV555, LY-CoV016, REGN10933, REGN10987 and CT-P59) completely lost neutralizing activity against B.1.1.529 virus in both Vero-TMPRSS2 and Vero-hACE2-TMPRSS2 cells, whereas others were reduced (COV2-2196 and COV2-2130 combination, ~12-fold decrease) or minimally affected (S309). Our results suggest that several, but not all, of the antibodies in clinical use might lose efficacy against the B.1.1.529 Omicron variant.